Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription

Articles published in
J Urol
    May 2018
  1. MAKELA VJ, Kotsar A, Tammela TL, Murtola TJ, et al
    Bladder cancer survival in men using 5-alpha-reductase inhibitors.
    J Urol. 2018 May 3. pii: S0022-5347(18)43085-6. doi: 10.1016/j.juro.2018.
    >> Share

  2. ATALA A
    Re: Evasion of Immunosurveillance by Genomic Alterations of PPARgamma/RXRalpha in Bladder Cancer.
    J Urol. 2018;199:1115-1116.
    >> Share

    Re: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    J Urol. 2018;199:1111-1112.
    >> Share

    Re: Intravesical rAd-IFNalpha/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Urol. 2018;199:1110-1111.
    >> Share

    April 2018
    Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Urol. 2018;199:891-892.
    >> Share

    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    J Urol. 2018;199:891-892.
    >> Share

    March 2018
  7. KAPADIA AA, Acevedo AM, Liu JJ, Garzotto M, et al
    Unconventional Bladder Preservation: Factors predicting Failure to Receive Definitive Surgery following Chemotherapy for Non-metastatic Muscle Invasive Bladder Cancer within the National Cancer Database.
    J Urol. 2018 Mar 15. pii: S0022-5347(18)42581-5. doi: 10.1016/j.juro.2018.
    >> Share

  8. PERLIS N, Krahn MD, Boehme KE, Alibhai SM, et al
    The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
    J Urol. 2018 Mar 9. pii: S0022-5347(18)42498-6. doi: 10.1016/j.juro.2018.
    >> Share

    February 2018
  9. UHLIG A, Amir Hosseini AS, Simon J, Lotz J, et al
    Gender-specific differences in disease-free, cancer-specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39380-7. doi: 10.1016/j.juro.2017.
    >> Share

  10. CHANG SS
    Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer.
    J Urol. 2018;199:341-342.
    >> Share

  11. CHANG SS
    Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin.
    J Urol. 2018;199:340-342.
    >> Share

    January 2018
  12. ZARGAR H, Shah JB, van Rhijn BW, Daneshmand S, et al
    Neoadjuvant dose dense MVAC versus GC in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy.
    J Urol. 2018 Jan 9. pii: S0022-5347(18)30036-3. doi: 10.1016/j.juro.2017.
    >> Share

  13. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer.
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30006-5. doi: 10.1016/j.juro.2017.
    >> Share

  14. CHANG SS
    Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guerin: Results from European Organ
    J Urol. 2018;199:26.
    >> Share

  15. CHANG SS
    Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    J Urol. 2018;199:25-26.
    >> Share

    December 2017
  16. CHANG SS
    Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Urol. 2017;198:1208.
    >> Share

  17. DANESHMAND S, Patel S, Lotan Y, Pohar K, et al
    Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (Hal) in the Surveillance of Bladder Cancer: A Phase Iii, Comparative, Multi-Center Study.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.
    >> Share

    November 2017
  18. CASILLA-LENNON MM, Choi SK, Deal AM, Bensen JT, et al
    Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life.
    J Urol. 2017 Nov 16. pii: S0022-5347(17)77917-7. doi: 10.1016/j.juro.2017.
    >> Share

  19. KOUMPAN Y, Jaeger M, Mizubuti GB, Tanzola R, et al
    Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Non-Muscle Invasive Bladder Cancer.
    J Urol. 2017 Nov 14. pii: S0022-5347(17)77909-8. doi: 10.1016/j.juro.2017.
    >> Share

  20. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.
    >> Share

  21. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.
    >> Share

  22. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.
    >> Share

  23. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.
    >> Share

  24. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.
    >> Share

    October 2017
  25. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    >> Share

  26. RYAN S, Serrell EC, Karabon P, Mills G, et al
    The Association Between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77715-4. doi: 10.1016/j.juro.2017.
    >> Share

    September 2017
  27. CHANG SS
    Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation.
    J Urol. 2017;198:482-483.
    >> Share

  28. CHANG SS
    Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    J Urol. 2017;198:482-483.
    >> Share

  29. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    >> Share

    August 2017
  30. NARAYAN VM, Adejoro O, Schwartz I, Ziegelmann M, et al
    The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77411-3. doi: 10.1016/j.juro.2017.
    >> Share

  31. SMITH ZL, Johnson SC, Golan S, McGinnis JR, et al
    Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77409-5. doi: 10.1016/j.juro.2017.
    >> Share

  32. HURLE R, Lazzeri M, Vanni E, Lughezzani G, et al
    Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project.
    J Urol. 2017 Aug 25. pii: S0022-5347(17)77391-0. doi: 10.1016/j.juro.2017.
    >> Share

  33. ATALA A
    Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo.
    J Urol. 2017;198:258-259.
    >> Share

  34. CHANG SS
    Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    J Urol. 2017;198:255.
    >> Share

    July 2017
  35. CHANG SS
    Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    J Urol. 2017;198:40.
    >> Share

  36. CHANG SS
    Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    J Urol. 2017;198:39-41.
    >> Share

    June 2017
  37. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    >> Share

    Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel.
    J Urol. 2017;197:1437-1438.
    >> Share

    April 2017
  39. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
    J Urol. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.
    >> Share

  40. RAVVAZ K, Walz ME, Weissert JA, Downs TM, et al
    Predicting non-muscle invasive bladder cancer recurrence and progression in a US population.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54785-0. doi: 10.1016/j.juro.2017.
    >> Share

    March 2017
  41. KIM JH, Chung BI
    Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and
    J Urol. 2017 Mar 29. pii: S0022-5347(17)30226-4. doi: 10.1016/j.juro.2017.
    >> Share

  42. BOEHM BE, Cornell JE, Wang H, Mukherjee N, et al
    Efficacy of Bacillus Calmette-guerin Strains for the Treatment of non-muscle Invasive Bladder Cancer: a Systematic Review and Network Meta-analysis.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39246-7. doi: 10.1016/j.juro.2017.
    >> Share

  43. TOBERT CM, Hamilton-Reeves JM, Norian LA, Hung C, et al
    The Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications on Cystectomy for Bladder Cancer.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39247-9. doi: 10.1016/j.juro.2017.
    >> Share

  44. CHANG SS
    Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer.
    J Urol. 2017;197.
    >> Share

    February 2017
    Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Gr
    J Urol. 2017 Feb 6. pii: S0022-5347(16)32070-5. doi: 10.1016/j.juro.2016.
    >> Share

    January 2017
  46. CHANG SS
    Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;197:52-54.
    >> Share

    December 2016
  47. BEUKERS W, van der Keur KA, Kandimalla R, Vergouwe Y, et al
    FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.
    J Urol. 2016 Dec 31. pii: S0022-5347(16)32099-7. doi: 10.1016/j.juro.2016.
    >> Share

  48. SHENOY SP, Marla PK, Sharma P, Batchu CK, et al
    Re: Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T
    J Urol. 2016 Dec 28. pii: S0022-5347(16)31927-9. doi: 10.1016/j.juro.2016.
    >> Share

  49. CHOU R, Selph S, Buckley DI, Fu R, et al
    Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2016 Dec 24. pii: S0022-5347(16)32091-2. doi: 10.1016/j.juro.2016.
    >> Share

    October 2016
  50. CHOU R, Selph S, Buckley DI, Fu R, et al
    Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis.
    J Urol. 2016 Oct 22. pii: S0022-5347(16)31585-3. doi: 10.1016/j.juro.2016.
    >> Share

  51. ATALA A
    Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness.
    J Urol. 2016;196:1314.
    >> Share

  52. CHANG SS
    Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer.
    J Urol. 2016;196:1045.
    >> Share

  53. CHANG SS
    Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study.
    J Urol. 2016;196:1045-6.
    >> Share

  54. CHANG SS
    Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study.
    J Urol. 2016;196:1044-6.
    >> Share

    August 2016
  55. SHIOTA M, Kiyoshima K, Yokomizo A, Takeuchi A, et al
    Suppressed recurrent bladder cancer after androgen suppression with androgen-deprivation therapy or 5alpha-reductase inhibitor.
    J Urol. 2016 Aug 6. pii: S0022-5347(16)30971-5. doi: 10.1016/j.juro.2016.
    >> Share

    Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
    J Urol. 2016;196:352-4.
    >> Share

  57. CHANG SS
    Re: Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival.
    J Urol. 2016;196:351-2.
    >> Share

    July 2016
  58. BIRENDRA R, Kekre NS
    Re: A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer: J. C. Park, N. M. Gandhi, M. A. Carducci, M. A. Eisenberger, A. S. Baras, G. J. Netto, J. J. Li
    J Urol. 2016 Jul 6. pii: S0022-5347(16)30545-6. doi: 10.1016/j.juro.2016.
    >> Share

    June 2016
  59. CHANG SS, Boorjian SA, Chou R, Clark PE, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    J Urol. 2016 Jun 15. pii: S0022-5347(16)30629-2. doi: 10.1016/j.juro.2016.
    >> Share

  60. OZGUR BC, Yuceturk CN
    Re: Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer: M. L. Blute, Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard and T. M. Downs J
    J Urol. 2016 Jun 10. pii: S0022-5347(16)30357-3. doi: 10.1016/j.juro.2016.
    >> Share

  61. ZHANG S, Zhong G, He W, Yu H, et al
    LncRNA Up-regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence.
    J Urol. 2016 Jun 4. pii: S0022-5347(16)30559-6. doi: 10.1016/j.juro.2016.
    >> Share

  62. CHANG SS
    Re: Variation in Performance of Candidate Surgical Quality Measures for Muscle-Invasive Bladder Cancer by Hospital Type.
    J Urol. 2016;195:1721-2.
    >> Share

  63. CHANG SS
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-Invasive Bladder Cancer: A Sign of Changing Tides.
    J Urol. 2016;195:1721.
    >> Share

  64. CHANG SS
    Re: Cost-Effectiveness of Neoadjuvant Chemotherapy before Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Urol. 2016;195:1720-2.
    >> Share

    May 2016
  65. MOSSANEN M, Macleod LC, Chu A, Wright JL, et al
    Comparative effectiveness of a patient centered pathology report for bladder cancer care.
    J Urol. 2016 May 19. pii: S0022-5347(16)30455-4. doi: 10.1016/j.juro.2016.
    >> Share

  66. LARA J, Brunson A, Keegan TH, Malogolowkin M, et al
    Determinants of survival in adolescents and young adults with urothelial bladder cancer: results from the California Cancer Registry.
    J Urol. 2016 May 18. pii: S0022-5347(16)30454-2. doi: 10.1016/j.juro.2016.
    >> Share

  67. GREGG JR, Emeruwa C, Wong J, Barocas DA, et al
    Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women.
    J Urol. 2016 May 6. pii: S0022-5347(16)30355-X. doi: 10.1016/j.juro.2016.
    >> Share

  68. CHANG SS
    Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients.
    J Urol. 2016;195:1382.
    >> Share

    Re: Recurrence Patterns after Open and Robot-Assisted Radical Cystectomy for Bladder Cancer.
    J Urol. 2016;195:1379-80.
    >> Share

  70. WANG DS
    Re: Long-Term Changes in Renal Function Outcomes following Radical Cystectomy and Urinary Diversion.
    J Urol. 2016;195:1511.
    >> Share

  71. MOREY AF
    Re: Outcomes of the Endoscopic Treatment of Bladder Neck Contractures in the Orthotopic Neobladder.
    J Urol. 2016;195:1508-9.
    >> Share

  72. CHANG SS
    Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience.
    J Urol. 2016;195:1381-2.
    >> Share

    Editorial Comment.
    J Urol. 2016;195:1375.
    >> Share

  74. KRISHNAN N, Liu X, Lavieri MS, Hu M, et al
    A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.
    J Urol. 2016;195:1362-7.
    >> Share

  75. HUSSEIN AA, Hashmi Z, Dibaj S, Altartir T, et al
    Reoperations following Robot-Assisted Radical Cystectomy: A Decade of Experience.
    J Urol. 2016;195:1368-76.
    >> Share

    April 2016
  76. SEILER R, Lam LL, Erho N, Takhar M, et al
    Prediction of lymph node metastasis in bladder cancer patients using whole transcriptome gene expression signatures.
    J Urol. 2016 Apr 19. pii: S0022-5347(16)30204-X. doi: 10.1016/j.juro.2016.
    >> Share

  77. CHANG SS
    Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody.
    J Urol. 2016;195.
    >> Share

  78. ATALA A
    Re: Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer.
    J Urol. 2016;195.
    >> Share

    Re: Use of Preoperative Performance Status and Hemoglobin Concentration to Predict Overall Survival for Patients Aged >/=75 Years after Radical Cystectomy for Treatment of Bladder Cancer.
    J Urol. 2016;195.
    >> Share

    Re: Does Radical Cystectomy Outperform Other Bladder Preservative Treatments in Elderly Patients with Advanced Bladder Cancer?
    J Urol. 2016;195.
    >> Share

    Re: Different Patterns in the Prognostic Value of Age for Bladder Cancer-Specific Survival Depending on Tumor Stages.
    J Urol. 2016;195.
    >> Share

  82. PATEL S, Cookson MS
    Radical Cystectomy-The Waiting is the Hardest Part...or is it?
    J Urol. 2016;195.
    >> Share

    March 2016
    Blue Light Cystoscopy Should Be Used Routinely for Bladder Cancer Detection.
    J Urol. 2016 Mar 16. pii: S0022-5347(16)03458-3. doi: 10.1016/j.juro.2016.
    >> Share

    Blue Light Cystoscopy Should Be Used Routinely for Bladder Cancer Detection.
    J Urol. 2016 Mar 16. pii: S0022-5347(16)03459-5. doi: 10.1016/j.juro.2016.
    >> Share

  85. CHANG SS
    Re: Conditional Survival after Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time.
    J Urol. 2016;195:610-1.
    >> Share

  86. CHANG SS
    Re: Factors Influencing the Length of Stay after Radical Cystectomy: Implications for Cancer Care and Perioperative Management.
    J Urol. 2016;195:610.
    >> Share

    February 2016
  87. BHATTAR R, Priyadarshi S, Tomar V, Yadav SS, et al
    Re: Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer: M. L. Blute, Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard and T. M. Downs J
    J Urol. 2016 Feb 11. pii: S0022-5347(16)00010-0. doi: 10.1016/j.juro.2015.
    >> Share

  88. GAN C, Amery S, Chatterton K, Khan MS, et al
    Sequential BCG / Electromotive drug administration Mitomycin C (EMDA-MMC) as the standard intravesical regimen in high risk non muscle invasive bladder cancer (HR-NMIBC) - two year outcomes.
    J Urol. 2016 Feb 1. pii: S0022-5347(16)00226-3. doi: 10.1016/j.juro.2016.
    >> Share

    Re: Multiparametric MRI Findings of Granulomatous Prostatitis after Intravesical bacillus Calmette-Guerin Therapy in a Patient Undergoing Active Surveillance.
    J Urol. 2016;195:371.
    >> Share

  90. CHANG SS
    Re: Adjuvant Cisplatin-Based Combined Chemotherapy for Lymph Node (LN)-Positive Urothelial Carcinoma of the Bladder (UCB) after Radical Cystectomy (RC): A Retrospective International Study of >1500 Patients.
    J Urol. 2016;195:300.
    >> Share

  91. CHANG SS
    Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma.
    J Urol. 2016;195:299-300.
    >> Share

    Editorial Comment.
    J Urol. 2016;195:289.
    >> Share

  93. BARTSCH G JR, Mitra AP, Mitra SA, Almal AA, et al
    Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.
    J Urol. 2016;195:493-8.
    >> Share

  94. OING C, Rink M, Oechsle K, Seidel C, et al
    Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    J Urol. 2016;195:254-63.
    >> Share

  95. SONPAVDE G, Pond GR, Rosenberg JE, Bajorin DF, et al
    Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
    J Urol. 2016;195:277-82.
    >> Share

    January 2016
  96. LEITNER CV, Ederer IA, de Martino M, Hofbauer SL, et al
    Dynamic prognostication using conditional recurrence and progression estimates for patients with non-muscle invasive bladder cancer.
    J Urol. 2016 Jan 30. pii: S0022-5347(16)00225-1. doi: 10.1016/j.juro.2016.
    >> Share

  97. MAMTANI R, Yang YX, Scott FI, Lewis JD, et al
    Association between itraconazole, a hedgehog-inhibitor, and bladder cancer.
    J Urol. 2016 Jan 23. pii: S0022-5347(16)00128-2. doi: 10.1016/j.juro.2016.
    >> Share

  98. VON RUNDSTEDT FC, Kimal R, Ma J, Arnold J, et al
    Integrative pathway analysis of metabolic signature in bladder cancer - a linkage to the Cancer Genome Atlas Project and prediction of survival.
    J Urol. 2016 Jan 21. pii: S0022-5347(16)00072-0. doi: 10.1016/j.juro.2016.
    >> Share

  99. SHARMA P, Henriksen CH, Zargar-Shoshtari K, Xin R, et al
    Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy.
    J Urol. 2016;195:47-52.
    >> Share

  100. NOGUERA-ORTEGA E, Rabanal RM, Secanella-Fandos S, Torrents E, et al
    gamma Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria.
    J Urol. 2016;195:198-205.
    >> Share

  101. LANGLE YV, Belgorosky D, Prack McCormick B, Sahores A, et al
    FGFR3 Down-Regulation is Involved in bacillus Calmette-Guerin Induced Bladder Tumor Growth Inhibition.
    J Urol. 2016;195:188-97.
    >> Share

  102. WANG DS
    Re: Intraoperative Continuous Norepinephrine Infusion Combined with Restrictive Deferred Hydration Significantly Reduces the Need for Blood Transfusion in Patients Undergoing Open Radical Cystectomy: Results of a Prospective Randomised Trial.
    J Urol. 2016;195:65.
    >> Share

  103. WANG DS
    Re: Perioperative Complications and 90-Day Mortality of Radical Cystectomy in the Elderly (75+): A Retrospective, Multicentre Study.
    J Urol. 2016;195:65.
    >> Share

  104. CHANG SS
    Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial.
    J Urol. 2016;195:63-4.
    >> Share

  105. HOMMA Y, Nakagawa T
    Optimal Dose and Duration of bacillus Calmette-Guerin Therapy for Urothelial Carcinoma of the Bladder.
    J Urol. 2016;195:9-10.
    >> Share

  106. LERNER SP
    Editorial Comment.
    J Urol. 2016;195:59.
    >> Share

    December 2015
  107. MATIN SF, Sfakianos JP, Espiritu PN, Coleman JA, et al
    Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates.
    J Urol. 2015;194:1567-74.
    >> Share

  108. WEIN AJ
    Re: The Microbiome of the Urinary Tract--A Role Beyond Infection.
    J Urol. 2015;194:1643-4.
    >> Share

  109. WANG DS
    Re: Health-Related Quality of Life after Radical Cystectomy and Neobladder Reconstruction in Women: Impact of Voiding and Continence Status.
    J Urol. 2015;194:1585.
    >> Share

  110. WANG DS
    Re: Impact of Surgeon Volume on the Morbidity and Costs of Radical Cystectomy in the USA: A Contemporary Population-Based Analysis.
    J Urol. 2015;194:1585-6.
    >> Share

  111. LAGUNA MP
    Re: Risk Stratification for Bladder Recurrence of Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy.
    J Urol. 2015;194:1582-3.
    >> Share

    November 2015
  112. PARK JC, Gandhi NM, Carducci MA, Eisenberger MA, et al
    A Retrospective Analysis of the Effect of Time from Diagnosis to Cystectomy on Survival in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy.
    J Urol. 2015 Nov 17. pii: S0022-5347(15)05238-6. doi: 10.1016/j.juro.2015.
    >> Share

  113. JAMES AC, Izard JP, Holt SK, Calvert JK, et al
    Root-Causes and Modifiability of 30-day Hospital Readmissions Following Radical Cystectomy for Bladder Cancer Under 65 Years of Age.
    J Urol. 2015 Nov 7. pii: S0022-5347(15)05203-9. doi: 10.1016/j.juro.2015.
    >> Share

  114. SEFTEL AD
    Re: Evaluating Sexual Function in Women after Radical Cystectomy as Treatment for Bladder Cancer.
    J Urol. 2015;194:1232.
    >> Share

  115. PENSON DF
    Re: Lower Urinary Tract Symptoms and Risk of Bladder Cancer in Men: Results from the Health Professionals Follow-up Study.
    J Urol. 2015;194:1231-2.
    >> Share

  116. CHANG SS
    Re: Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients.
    J Urol. 2015;194:1230.
    >> Share

  117. KLATTE T, Seitz C, Rink M, Roupret M, et al
    ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    J Urol. 2015;194:1456-62.
    >> Share

  118. TAYLOR JA 3RD
    Editorial Comment.
    J Urol. 2015;194:1208.
    >> Share

  119. XU W, Daneshmand S, Bazargani ST, Cai J, et al
    Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway.
    J Urol. 2015;194:1209-13.
    >> Share

    October 2015
  120. VAN OSCH FH, Jochems SH, van Schooten FJ, Bryan RT, et al
    Significant role for lifetime cigarette smoking in worsening bladder cancer and upper tract urothelial carcinoma prognosis: a meta-analysis.
    J Urol. 2015 Oct 30. pii: S0022-5347(15)05162-9. doi: 10.1016/j.juro.2015.
    >> Share

  121. ZARGAR H, Zargar-Shoshtari K, Lotan Y, Shah JB, et al
    Final Pathologic Stage after Neoadjuvant Chemotherapy and Radical Cystectomy For Bladder Cancer: Does pT0 Predict Better Survival Than pTa/Tis/T1?
    J Urol. 2015 Oct 29. pii: S0022-5347(15)05153-8. doi: 10.1016/j.juro.2015.
    >> Share

  122. LIN YC, Lin JF, Wen SI, Yang SC, et al
    Inhibition of High Basal Level of Autophagy Induces Apoptosis in Human Bladder Cancer Cells.
    J Urol. 2015 Oct 28. pii: S0022-5347(15)05148-4. doi: 10.1016/j.juro.2015.
    >> Share

  123. LAMM DL
    Getting the Most Out of Bacillus Calmette-Guerin for Treatment of Bladder Cancer.
    J Urol. 2015 Oct 8. pii: S0022-5347(15)04960-5. doi: 10.1016/j.juro.2015.
    >> Share

  124. ATALA A
    Re: Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival following Radiotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2015;194:1162-3.
    >> Share

  125. CHANG SS
    Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer.
    J Urol. 2015;194:956.
    >> Share

  126. CHANG SS
    Re: Potential Impact of 18F-FDG PET/CT on Patients Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    J Urol. 2015;194:955-6.
    >> Share

  127. CHANG SS
    Re: Metastases in Normal-Sized Pelvic Lymph Nodes: Detection with Diffusion-Weighted MR Imaging.
    J Urol. 2015;194:954-5.
    >> Share

    September 2015
  128. BROOKS M, Godoy G, Sun M, Shariat SF, et al
    External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival, and Overall Survival Following Radical Cystectomy.
    J Urol. 2015 Sep 4. pii: S0022-5347(15)04716-3. doi: 10.1016/j.juro.2015.
    >> Share

  129. BANERJEE I, Yadav S, Priyadarshi S, Tomar V, et al
    Re: Clinical Outcomes of cT1 Micropapillary Bladder Cancer: D. L. Willis, M. I. Fernandez, R. J. Dickstein, S. Parikh, J. B. Shah, L. L. Pisters, C. C. Guo, S. Henderson, B. A. Czerniak, H. B. Grossman, C. P. Dinney and A. M. Kamat J Urol 2015;193:112
    J Urol. 2015 Sep 3. pii: S0022-5347(15)04139-7. doi: 10.1016/j.juro.2015.
    >> Share

  130. PENSON DF
    Re: Association between Cannabis Use and the Risk of Bladder Cancer: Results from the California Men's Health Study.
    J Urol. 2015;194:667.
    >> Share

  131. CHANG SS
    Re: Contemporary Cost-Effectiveness Analysis Comparing Sequential bacillus Calmette-Guerin and Electromotive Mitomycin versus bacillus Calmette-Guerin Alone for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2015;194:666.
    >> Share

  132. GUPTA A, Long JB, Chen J, Gross CP, et al
    Risk of Vascular Toxicity with Platinum-based Chemotherapy in Elderly Patients with Bladder Cancer.
    J Urol. 2015 Sep 1. pii: S0022-5347(15)04708-4. doi: 10.1016/j.juro.2015.
    >> Share

    August 2015
  133. VAN KESSEL KE, Van Neste L, Lurkin I, Zwarthoff EC, et al
    Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Hematuria Patients.
    J Urol. 2015 Aug 28. pii: S0022-5347(15)04705-9. doi: 10.1016/j.juro.2015.
    >> Share

  134. SATHE A, Koshy N, Schmid SC, Thalgott M, et al
    CDK4/6-inhibition controls proliferation of bladder cancer and transcription of RB1.
    J Urol. 2015 Aug 26. pii: S0022-5347(15)04685-6. doi: 10.1016/j.juro.2015.
    >> Share

  135. YOKOMIZO A, Kanimoto Y, Okamura T, Ozono S, et al
    Randomized Controlled Study of the Efficacy, Safety and Quality of Life of Low-Dose Bacillus Calmette-Guerin Instillation Therapy for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2015 Aug 22. pii: S0022-5347(15)04674-1. doi: 10.1016/j.juro.2015.
    >> Share

  136. CHANG SS
    Re: Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer.
    J Urol. 2015;194:334-5.
    >> Share

    Editorial Comment.
    J Urol. 2015;194:439.
    >> Share

  138. FU LY, Adeniran AJ
    Adenocarcinoma Arising from a Bladder Diverticulum.
    J Urol. 2015;194:527-8.
    >> Share

  139. WANG B, Wu S, Zeng H, Liu Z, et al
    CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    J Urol. 2015;194:556-62.
    >> Share

    July 2015
  140. SMITH ND, Prasad SM, Patel AR, Weiner AB, et al
    Bladder Cancer Mortality in the United States: A Geographic and Temporal Analysis of Socioeconomic and Environmental Factors.
    J Urol. 2015 Jul 30. pii: S0022-5347(15)04499-7. doi: 10.1016/j.juro.2015.
    >> Share

  141. ZARGAR-SHOSHTARI K, Zargar H, Lotan Y, Shah JB, et al
    A Multi-Institutional Analysis of Outcomes in Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
    J Urol. 2015 Jul 20. pii: S0022-5347(15)04421-3. doi: 10.1016/j.juro.2015.
    >> Share

  142. PIERZYNSKI JA, Hildebrandt MA, Kamat AM, Lin J, et al
    Genetic Variants within the Wnt/beta-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk.
    J Urol. 2015 Jul 11. pii: S0022-5347(15)04361-X. doi: 10.1016/j.juro.2015.
    >> Share

  143. BLUTE ML JR, Rushmer TJ, Shi F, Fuller B, et al
    Renin-Angiotensin Inhibitors Decrease Recurrence After Turbt in Non-Muscle Invasive Bladder Cancer.
    J Urol. 2015 Jul 11. pii: S0022-5347(15)04360-8. doi: 10.1016/j.juro.2015.
    >> Share

  144. CHANG SS
    Re: Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors.
    J Urol. 2015;194:261.
    >> Share

  145. GEIJSEN ED, de Reijke TM, Koning CC, Zum Vorde Sive Vording PJ, et al
    Combining Mitomycin C and regional 70 MHz hyperthermia in patients with non-muscle invasive bladder cancer: a pilot study.
    J Urol. 2015 Jul 1. pii: S0022-5347(15)04307-4. doi: 10.1016/j.juro.2015.
    >> Share

  146. CHANG SS
    Re: Intermediate-Term Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Urothelial Carcinoma.
    J Urol. 2015;194:44.
    >> Share

  147. FAN EW, Li CC, Wu WJ, Huang CN, et al
    FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
    J Urol. 2015;194:223-9.
    >> Share

  148. GIRI V, Jha AK, Tomar V, Banerjee I, et al
    Re: Novel Bladder Preservation Therapy with Osaka Medical College Regimen: H. Azuma, T. Inamoto, K. Takahara, H. Nomi, H. Hirano, N. Ibuki, H. Uehara, K. Komura, K. Minami, T. Uchimoto, K. Saito, T. Takai, N. Tanda, K. Yamamoto, Y. Narumi and S. Kiyam
    J Urol. 2015;194:263.
    >> Share

    June 2015
  149. HEMDAN T, Malmstrom PU, Jahnson S, Segersten U, et al
    Emmprin expression predict response and survival following cisplatin-containing chemotherapy - A validation study in bladder cancer patients from two randomized studies of cystectomy with and without neoadjuvant chemotherapy.
    J Urol. 2015 Jun 25. pii: S0022-5347(15)04296-2. doi: 10.1016/j.juro.2015.
    >> Share

  150. LUCHEY AM, Lin HY, Yue B, Agarwal G, et al
    Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer.
    J Urol. 2015 Jun 5. pii: S0022-5347(15)04113-0. doi: 10.1016/j.juro.2015.
    >> Share

  151. HAYASHI T, Seiler R, Oo HZ, Jager W, et al
    Targeting HER2 with T-DM1, an Antibody-cytotoxic Drug Conjugate, is effective in HER2-overexpressing bladder cancer.
    J Urol. 2015 Jun 2. pii: S0022-5347(15)04105-1. doi: 10.1016/j.juro.2015.
    >> Share

  152. CHANG SS
    Re: Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study with Molecular Correlates of Response and Toxicit
    J Urol. 2015;193:1932.
    >> Share

  153. CHANG SS
    Re: long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    J Urol. 2015;193:1931-2.
    >> Share

  154. GANGKAK G, Giri V, Yadav SS
    Re: Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer: S. Daneshmand, H. Ahmadi, A. K. Schuckman, A. P. Mitra, J. Cai, G. Miranda and H. Djaladat J Urol 2014;192:50-56.
    J Urol. 2015 Jun 1. pii: S0022-5347(15)03726-X. doi: 10.1016/j.juro.2015.02.2950
    >> Share

  155. BANERJEE I, Giri V, Tomar V
    Re: The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A. Meyer, R. Ghandour, A. Bergman, C. Castaneda, M. Wosnitzer, G. Hruby, M. Benson and J. McKiernan J Urol 2014; 192: 696-70
    J Urol. 2015;193:2152.
    >> Share

    May 2015
  156. CHAN KG, Collins JW, Wiklund NP
    Robot-assisted radical cystectomy: extracorporeal vs intracorporeal urinary diversion.
    J Urol. 2015;193:1467-9.
    >> Share

  157. FRYE TP, Sadowski DJ, Zahnd WE, Jenkins WD, et al
    Impact of county rurality and urologist density on urological cancer mortality in illinois.
    J Urol. 2015;193:1608-13.
    >> Share

  158. PSUTKA SP, Boorjian SA, Moynagh MR, Schmit GD, et al
    Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting.
    J Urol. 2015;193:1507-13.
    >> Share

  159. PARKER WP, Ho PL, Melquist JJ, Scott K, et al
    The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
    J Urol. 2015;193:1494-9.
    >> Share

  160. SKOLARUS TA, Jacobs BL, Schroeck FR, He C, et al
    Understanding hospital readmission intensity after radical cystectomy.
    J Urol. 2015;193:1500-6.
    >> Share

  161. DOWNS TM
    Reducing readmissions and mortality after radical cystectomy.
    J Urol. 2015;193:1461-2.
    >> Share

  162. ODISHO AY
    Editorial comment.
    J Urol. 2015;193:1613.
    >> Share

  163. Reply by author.
    J Urol. 2015;193:1613-4.
    >> Share

    March 2015
  164. ATALA A
    Re: Mutations in 3'-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb.
    J Urol. 2015;193:1061.
    >> Share

  165. ROUANNE M, Lebret T, Courbebaisse M
    Re: Long-term renal function outcomes after radical cystectomy.
    J Urol. 2015;193:1066-7.
    >> Share

  166. WU TF, Li CF, Chien LH, Shen KH, et al
    Galectin-1 dysregulation independently predicts disease specific survival in bladder urothelial carcinoma.
    J Urol. 2015;193:1002-8.
    >> Share

    February 2015
  167. DOWNS T
    Editorial comment.
    J Urol. 2015;193:450.
    >> Share

  168. DREICER R
    Interdisciplinary management of locally advanced and metastatic genitourinary cancers: a team sport.
    J Urol. 2015;193:389-90.
    >> Share

  169. LAU CS, Blackwell RH, Quek ML
    Radical cystectomy: open vs robotic approach.
    J Urol. 2015;193:400-2.
    >> Share

  170. GLEASON JM, Bowlin PR, Bagli DJ, Lorenzo AJ, et al
    A comprehensive review of pediatric urachal anomalies and predictive analysis for adult urachal adenocarcinoma.
    J Urol. 2015;193:632-6.
    >> Share

  171. YOUSSEF RF, von Rundstedt FC, Kapur P, Mosbah A, et al
    Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma.
    J Urol. 2015;193:451-6.
    >> Share

  172. SUN AJ, Djaladat H, Schuckman A, Miranda G, et al
    Venous thromboembolism following radical cystectomy: significant predictors, comparison of different anticoagulants and timing of events.
    J Urol. 2015;193:565-9.
    >> Share

    October 2014
  173. ZABELL JR, Adejoro O, Konety BR, Weight CJ, et al
    Risk of End-Stage Kidney Disease after Radical Cystectomy According to Urinary Diversion Type.
    J Urol. 2014 Oct 31. pii: S0022-5347(14)04805-8. doi: 10.1016/j.juro.2014.
    >> Share

    August 2014
  174. AZUMA H, Inamoto T, Takahara K, Nomi H, et al
    Novel Bladder Preservation Therapy, OMC-Regimen: Combined Therapy using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis with Concurrent Radiation.
    J Urol. 2014 Aug 25. pii: S0022-5347(14)04349-3. doi: 10.1016/j.juro.2014.
    >> Share

    July 2014
  175. HERR HW
    The Risk of Urinary Tract Infection after Flexible Cystoscopy in Bladder Tumor Patients who did not receive Prophylactic Antibiotics.
    J Urol. 2014 Jul 18. pii: S0022-5347(14)03963-9. doi: 10.1016/j.juro.2014.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016